VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Abbott Laboratories vs EssilorLuxottica

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$195.3B
Gross margin (TTM)55.5%
Operating margin (TTM)18.2%
Net margin (TTM)14.7%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

EssilorLuxottica

EL · Euronext Paris

Market cap (USD)$110.3B
Gross margin (TTM)61.5%
Operating margin (TTM)12.4%
Net margin (TTM)8.5%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryFR
Data as of2026-01-11
Moat score
69/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into EssilorLuxottica's moat claims, evidence, and risks.

View EL analysis

Comparison highlights

  • Moat score gap: EssilorLuxottica leads (69 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices); EssilorLuxottica has 2 segments (52.7% in Direct to Consumer).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
  • Moat breadth: Abbott Laboratories has 10 moat types across 3 domains; EssilorLuxottica has 5 across 3.

Primary market context

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

EssilorLuxottica

Direct to Consumer

Market

Optical retail and e-commerce (prescription eyewear and sunglasses)

Geography

Global

Customer

Consumers (end-users)

Role

Omnichannel retailer + vertically integrated manufacturer/brand owner

Revenue share

52.7%

Side-by-side metrics

Abbott Laboratories
EssilorLuxottica
Ticker / Exchange
ABT - New York Stock Exchange
EL - Euronext Paris
Market cap (USD)
$195.3B
$110.3B
Gross margin (TTM)
55.5%
61.5%
Operating margin (TTM)
18.2%
12.4%
Net margin (TTM)
14.7%
8.5%
Sector
Healthcare
Healthcare
Industry
Medical - Devices
Medical - Instruments & Supplies
HQ country
US
FR
Primary segment
Cardiovascular & Electrophysiology Devices
Direct to Consumer
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
64 / 100
69 / 100
Moat domains
Demand, Legal, Supply
Legal, Supply, Demand
Last update
2025-12-30
2026-01-11

Moat coverage

Shared moat types

Brand TrustDistribution ControlScale Economies Unit CostIP Choke Point

Abbott Laboratories strengths

Procurement InertiaInstalled Base ConsumablesData Workflow LockinGovernment Contracting RelationshipsCompliance AdvantageTraining Org Change Costs

EssilorLuxottica strengths

Contractual Exclusivity

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

EssilorLuxottica segments

Full profile >

Professional Solutions

Oligopoly

47.3%

Direct to Consumer

Competitive

52.7%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.